Role of HSP70 in Pancreatic Diseases
Role of HSP70 in Pancreatic Diseases
批准号:
10396977
负责人:
Eli Gilboa
金额:
$32.15万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-24 至 2024-04-30
关键词:
Acinar CellAcuteAffectAggressive behaviorAnimal ModelApoptoticBiological AssayBiologyCXCL12 geneCell DeathCell SurvivalCellsClinical TrialsComprehensionCytotoxic T-LymphocytesDataDependenceDown-RegulationEnsureEvaluationGenetic EngineeringGrantGrowthHeat-Shock Proteins 70Heat-Shock ResponseHumanImmuneIn VitroInfiltrationMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMolecular ChaperonesNuclearPancreasPancreatic DiseasesPathway interactionsPatient-Focused OutcomesPhasePlayPropertyProteinsResearchRoleShapesSignal TransductionSpecimenStromal CellsSupporting CellT-Cell ActivationT-LymphocyteTestingTumor-infiltrating immune cellsWateracute pancreatitisanaloganti-cancerbasecancer cellcell injurychemokineheat-shock factor 1in vivoinhibitornovelnovel therapeuticsoverexpressionpancreatic cancer cellspancreatic cancer modelpreventtriptolidetumortumor growthtumor microenvironmenttumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Several protective mechanisms have evolved to ensure survival of cells under adverse condition. `Heat
Shock Response' is one such survival mechanism. We have previously shown that heat shock protein-70, a
multi-faceted chaperone protein protects pancreatic acinar cells from damage during acute pancreatitis. We
have extended these observations to pancreatic cancer and have demonstrated that (HSP70) is
overexpressed in pancreatic cancer cells and plays a very prominent role in protecting cancer cells from cell
death.
While previous research focused primarily on the properties of the cancer cell, there has recently been
increased understanding of the role of the tumor microenvironment (TME) in supporting cancer growth.
Pancreatic cancer has an intricate TME, which is believed to contribute to its aggressive behavior. While
studies in non-pancreatic tumors suggest that lack of Heat Shock Factor-1 (HSF1) in stroma decreases the
growth of, the role of heat shock response pathway in shaping the TME of pancreatic cancer has never been
studied.
Intriguingly, our data suggest that triptolide, a natural heat shock inhibitor modulates pancreatic cancer
TME and depletes stroma. Our preliminary data also suggest that lack of HSP70 in stromal cells is
associated with increased cytotoxic T cell infiltration. Furthermore, we have shown that depletion of HSP70
in immune cells, the other important component of TME, decreases growth of tumors and that T cells lacking
HSP70 are more effective in killing pancreatic cancer cells in vitro. These data suggest that Heat Shock
Response/ HSP70 in various components of TME (immune vs stroma) influence tumor growth and that
triptolide could influence TME by modulating heat shock response.
The current grant is focused towards understanding the role of Heat shock response in biology of
pancreatic cancer. In specific aim 1 we will confirm the role of stromal HSP70 and Heat Shock Response
(HSR) in pancreatic cancer growth using a variety of animal models of pancreatic cancer as well as human
specimens. In aim 2, we will elucidate the mechanism by which HSP70 and heat shock response in tumor
stroma promotes tumor growth. Specifically, we will elucidate if lack of stromal HSR leads to increased
efficacy of immune cells against cancer cells. Finally, in aim 3, we will elucidate the mechanism(s) by which
HSP70 and HSR in immune cells promote pancreatic cancer growth. Specifically, we will evaluate whether
HSP70/HSR in T cells affect T cell activation and T cell mediated killing. We believe that elucidation of the
mechanism by which HSP70/HSR in TME modulate pancreatic cancer progression will lead to increased
comprehension of the mechanism cancer cell uses to evade cell death.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Increased expression of collagen prolyl hydroxylases in ovarian cancer is associated with cancer growth and metastasis.
卵巢癌中胶原蛋白脯氨酰羟化酶表达的增加与癌症的生长和转移有关。
DOI:
--
发表时间:
2023
期刊:
American journal of cancer research
影响因子:
5.3
作者:
[Song,Mihae, Schnettler,Erica, Venkatachalam,Annapoorna, Wang,Yujun, Feldman,Lisa, Argenta,Peter, Rodriguez-Rodriguez,Lorna, Ramakrishnan,Sundaram]
通讯作者:
Ramakrishnan,Sundaram
DOI:
10.1016/j.canlet.2013.02.050
发表时间:
2013-07-28
期刊:
CANCER LETTERS
影响因子:
9.7
作者:
[Banerjee, Sulagna, Thayanithy, Venugopal, Sangwan, Veena, Mackenzie, Tiffany N., Saluja, Ashok K., Subramanian, Subbaya]
通讯作者:
Subramanian, Subbaya
DOI:
10.1038/labinvest.2015.46
发表时间:
2015-06
期刊:
Laboratory investigation; a journal of technical methods and pathology
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1016/j.oraloncology.2014.09.013
发表时间:
2014-12
期刊:
Oral oncology
影响因子:
4.8
作者:
[Caicedo-Granados E, Lin R, Fujisawa C, Yueh B, Sangwan V, Saluja A]
通讯作者:
Saluja A
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors
-
批准号:10664957
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2021
-
负责人:Eli Gilboa
-
依托单位:
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors
-
批准号:10456230
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2021
-
负责人:Eli Gilboa
-
依托单位:
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors
-
批准号:10265108
-
项目类别:
-
资助金额:$35.11万
-
财政年份:2021
-
负责人:Eli Gilboa
-
依托单位:
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs
-
批准号:9004624
-
项目类别:
-
资助金额:$75.98万
-
财政年份:2015
-
负责人:Eli Gilboa
-
依托单位:
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs
-
批准号:9220782
-
项目类别:
-
资助金额:$76.75万
-
财政年份:2015
-
负责人:Eli Gilboa
-
依托单位:
Enhancing Immunological Memory Using Aptamer targeted siRNA Delivery to T Cells
-
批准号:9180122
-
项目类别:
-
资助金额:$10.08万
-
财政年份:2014
-
负责人:Eli Gilboa
-
依托单位:
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
-
批准号:9379074
-
项目类别:
-
资助金额:$10.08万
-
财政年份:2014
-
负责人:Eli Gilboa
-
依托单位:
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
-
批准号:8760104
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2014
-
负责人:Eli Gilboa
-
依托单位:
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
-
批准号:8444571
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2011
-
负责人:Eli Gilboa
-
依托单位:
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
-
批准号:8101761
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2011
-
负责人:Eli Gilboa
-
依托单位:
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
-
批准号:8610902
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2011
-
负责人:Eli Gilboa
-
依托单位:
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
-
批准号:8815095
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2011
-
负责人:Eli Gilboa
-
依托单位:
Oligonucleotide aptamer ligands to reverse T cell anergy in HIV-infected patients
-
批准号:7841233
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Eli Gilboa
-
依托单位:
Oligonucleotide aptamer ligands to reverse T cell anergy in HIV-infected patients
-
批准号:8082732
-
项目类别:
-
资助金额:$22.72万
-
财政年份:2010
-
负责人:Eli Gilboa
-
依托单位:
Role of HSP70 in Pancreatic Diseases
-
批准号:9917706
-
项目类别:
-
资助金额:$42.33万
-
财政年份:2007
-
负责人:Eli Gilboa
-
依托单位:
Development of Oligonucleotide-based CTLA-4 Inhibitors
-
批准号:6861699
-
项目类别:
-
资助金额:$31.57万
-
财政年份:2004
-
负责人:Eli Gilboa
-
依托单位:
Development of Oligonucleotide-based CTLA-4 Inhibitors
-
批准号:7329729
-
项目类别:
-
资助金额:$16.78万
-
财政年份:2004
-
负责人:Eli Gilboa
-
依托单位:
Development of Oligonucleotide-based CTLA-4 Inhibitors
-
批准号:7231938
-
项目类别:
-
资助金额:$29.72万
-
财政年份:2004
-
负责人:Eli Gilboa
-
依托单位:
Development of Oligonucleotide-based CTLA-4 Inhibitors
-
批准号:7389526
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2004
-
负责人:Eli Gilboa
-
依托单位:
Development of Oligonucleotide-based CTLA-4 Inhibitors
-
批准号:7047742
-
项目类别:
-
资助金额:$13.68万
-
财政年份:2004
-
负责人:Eli Gilboa
-
依托单位:
海外基金